NCCN Guidelines® Insights - Gastrointestinal Stromal Tumors, Version 2.2014

Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma of the gastrointestinal tract, resulting most commonly from KIT or platelet-derived growth factor receptor α (PDGFRα)–activating mutations. These NCCN Guideline Insights highlight the important updates to the NCCN Guidelines for Soft Tissue Sarcoma specific to the management of patients with GIST experiencing disease progression while on imatinib and/or sunitinib.

Target Audience

This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Integrate into professional practice the updates to NCCN Guidelines for Gastrointestinal Stromal Tumors
  • Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Gastrointestinal Stromal Tumors
Additional information
Supporters: 

Supported by an independent educational grant from Prometheus Laboratories Inc., and by an education grant from Exelixis, Inc., and by educational grants from Bayer HealthCare, Onyx Pharmaceuticals, Inc., and Algeta US; Genentech; Genomic Health, Inc.; NOVOCURE; and Merck Sharp & Dohme Corp.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
06/16/2014
Course expires: 
06/16/2015
Cost:
$0.00

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician

Accreditation Period

Course opens: 
06/16/2014
Course expires: 
06/16/2015

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing